Jaguar Health, Inc. (JAGX): Nasdaq/NYSE listing notice — Jaguar Health receives Nasdaq delisting notice for insufficient publicly held shares after reverse split

Jaguar Health, Inc.

Post 1-for-35 reverse stock split on April 30, 2026, publicly held shares are ~401,226, below 500,000 minimum.
Nasdaq Staff notified company on May 1, 2026 of additional deficiency under Listing Rule 5550(a)(4).
Company must present views to Nasdaq Hearings Panel by May 8, 2026; failure may lead to delisting.
Company remains non-compliant with both minimum bid price and public shares requirements.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Jaguar Health, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4), 5810(d), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5550(a)(4), 5810(d), 5810(c)(3)(A)

Exact text from the filing

May 1, 2026, Jaguar Health, Inc. (the “Company”) received a written notification (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying th

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-202614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.